Penumbra, Inc. Announces Positive Clinical Results from BOLT-DVT Trial

Penumbra reported positive results from its BOLT-DVT IDE clinical trial, with a 98% thrombus removal rate and a 3.1% major adverse event rate at 48 hours. At 30 days, 84.3% of treated patients were free of post-thrombotic syndrome; patients also reported immediate, sustained pain relief and improved quality of life on the VEINES-QOL measure. The article did not report financial results or a stock-price reaction.